nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—PDE5A—penis—atherosclerosis	0.0312	0.211	CbGeAlD
Pentoxifylline—PDE5A—artery—atherosclerosis	0.0145	0.0975	CbGeAlD
Pentoxifylline—PDE5A—endothelium—atherosclerosis	0.0122	0.0824	CbGeAlD
Pentoxifylline—PDE5A—blood vessel—atherosclerosis	0.0113	0.076	CbGeAlD
Pentoxifylline—NT5E—connective tissue—atherosclerosis	0.0089	0.06	CbGeAlD
Pentoxifylline—NT5E—cardiovascular system—atherosclerosis	0.00774	0.0522	CbGeAlD
Pentoxifylline—NT5E—adipose tissue—atherosclerosis	0.00683	0.0461	CbGeAlD
Pentoxifylline—ADORA2B—adipose tissue—atherosclerosis	0.00585	0.0394	CbGeAlD
Pentoxifylline—PDE5A—connective tissue—atherosclerosis	0.00578	0.039	CbGeAlD
Pentoxifylline—ADORA2A—cardiovascular system—atherosclerosis	0.00552	0.0372	CbGeAlD
Pentoxifylline—PDE4A—adipose tissue—atherosclerosis	0.00521	0.0352	CbGeAlD
Pentoxifylline—PDE5A—cardiovascular system—atherosclerosis	0.00503	0.0339	CbGeAlD
Pentoxifylline—NT5E—liver—atherosclerosis	0.00479	0.0323	CbGeAlD
Pentoxifylline—ADORA1—cardiovascular system—atherosclerosis	0.00476	0.0321	CbGeAlD
Pentoxifylline—PDE5A—adipose tissue—atherosclerosis	0.00443	0.0299	CbGeAlD
Pentoxifylline—ADORA1—adipose tissue—atherosclerosis	0.0042	0.0283	CbGeAlD
Pentoxifylline—ADORA2A—liver—atherosclerosis	0.00341	0.023	CbGeAlD
Pentoxifylline—PDE4B—adipose tissue—atherosclerosis	0.00311	0.021	CbGeAlD
Pentoxifylline—Flatulence—Rosuvastatin—atherosclerosis	0.00253	0.00477	CcSEcCtD
Pentoxifylline—Hepatitis—Lovastatin—atherosclerosis	0.0025	0.00471	CcSEcCtD
Pentoxifylline—Hepatitis—Ezetimibe—atherosclerosis	0.00245	0.00462	CcSEcCtD
Pentoxifylline—Angioedema—Rosuvastatin—atherosclerosis	0.00234	0.00442	CcSEcCtD
Pentoxifylline—Hepatitis—Simvastatin—atherosclerosis	0.00233	0.00441	CcSEcCtD
Pentoxifylline—Jaundice—Niacin—atherosclerosis	0.00233	0.00439	CcSEcCtD
Pentoxifylline—Flushing—Lovastatin—atherosclerosis	0.00232	0.00437	CcSEcCtD
Pentoxifylline—Jaundice—Pravastatin—atherosclerosis	0.00229	0.00433	CcSEcCtD
Pentoxifylline—Sweating—Niacin—atherosclerosis	0.00229	0.00432	CcSEcCtD
Pentoxifylline—Flushing—Ezetimibe—atherosclerosis	0.00227	0.00429	CcSEcCtD
Pentoxifylline—Immune system disorder—Ezetimibe—atherosclerosis	0.00221	0.00417	CcSEcCtD
Pentoxifylline—Myalgia—Rosuvastatin—atherosclerosis	0.00218	0.00412	CcSEcCtD
Pentoxifylline—PDE4B—liver—atherosclerosis	0.00218	0.0147	CbGeAlD
Pentoxifylline—Flushing—Simvastatin—atherosclerosis	0.00217	0.00409	CcSEcCtD
Pentoxifylline—Haemoglobin—Niacin—atherosclerosis	0.00215	0.00407	CcSEcCtD
Pentoxifylline—Haemorrhage—Niacin—atherosclerosis	0.00214	0.00405	CcSEcCtD
Pentoxifylline—Hepatitis—Niacin—atherosclerosis	0.00214	0.00405	CcSEcCtD
Pentoxifylline—Flatulence—Lovastatin—atherosclerosis	0.00214	0.00404	CcSEcCtD
Pentoxifylline—Erythema—Ezetimibe—atherosclerosis	0.00213	0.00402	CcSEcCtD
Pentoxifylline—Dysgeusia—Lovastatin—atherosclerosis	0.00213	0.00402	CcSEcCtD
Pentoxifylline—Hepatitis—Pravastatin—atherosclerosis	0.00211	0.00398	CcSEcCtD
Pentoxifylline—Confusional state—Rosuvastatin—atherosclerosis	0.00211	0.00398	CcSEcCtD
Pentoxifylline—Back pain—Lovastatin—atherosclerosis	0.0021	0.00397	CcSEcCtD
Pentoxifylline—Flatulence—Ezetimibe—atherosclerosis	0.0021	0.00396	CcSEcCtD
Pentoxifylline—Muscle spasms—Lovastatin—atherosclerosis	0.00209	0.00394	CcSEcCtD
Pentoxifylline—Infection—Rosuvastatin—atherosclerosis	0.00208	0.00392	CcSEcCtD
Pentoxifylline—Back pain—Ezetimibe—atherosclerosis	0.00206	0.00389	CcSEcCtD
Pentoxifylline—Muscle spasms—Ezetimibe—atherosclerosis	0.00205	0.00387	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00205	0.00387	CcSEcCtD
Pentoxifylline—Vision blurred—Lovastatin—atherosclerosis	0.00205	0.00387	CcSEcCtD
Pentoxifylline—Tremor—Lovastatin—atherosclerosis	0.00204	0.00384	CcSEcCtD
Pentoxifylline—Erythema—Simvastatin—atherosclerosis	0.00203	0.00384	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Lovastatin—atherosclerosis	0.00202	0.00381	CcSEcCtD
Pentoxifylline—Flatulence—Simvastatin—atherosclerosis	0.002	0.00378	CcSEcCtD
Pentoxifylline—Dysgeusia—Simvastatin—atherosclerosis	0.00199	0.00376	CcSEcCtD
Pentoxifylline—Flushing—Niacin—atherosclerosis	0.00199	0.00376	CcSEcCtD
Pentoxifylline—Angioedema—Lovastatin—atherosclerosis	0.00198	0.00375	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00198	0.00373	CcSEcCtD
Pentoxifylline—Anaemia—Ezetimibe—atherosclerosis	0.00197	0.00372	CcSEcCtD
Pentoxifylline—Malaise—Lovastatin—atherosclerosis	0.00196	0.0037	CcSEcCtD
Pentoxifylline—Flushing—Pravastatin—atherosclerosis	0.00196	0.0037	CcSEcCtD
Pentoxifylline—Muscle spasms—Simvastatin—atherosclerosis	0.00195	0.00369	CcSEcCtD
Pentoxifylline—Angioedema—Ezetimibe—atherosclerosis	0.00195	0.00368	CcSEcCtD
Pentoxifylline—Leukopenia—Lovastatin—atherosclerosis	0.00194	0.00367	CcSEcCtD
Pentoxifylline—Malaise—Ezetimibe—atherosclerosis	0.00192	0.00363	CcSEcCtD
Pentoxifylline—Vision blurred—Simvastatin—atherosclerosis	0.00191	0.00362	CcSEcCtD
Pentoxifylline—Arrhythmia—Niacin—atherosclerosis	0.00191	0.00362	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00191	0.0036	CcSEcCtD
Pentoxifylline—Tremor—Simvastatin—atherosclerosis	0.0019	0.00359	CcSEcCtD
Pentoxifylline—Insomnia—Rosuvastatin—atherosclerosis	0.00189	0.00357	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Simvastatin—atherosclerosis	0.00189	0.00356	CcSEcCtD
Pentoxifylline—Arrhythmia—Pravastatin—atherosclerosis	0.00188	0.00356	CcSEcCtD
Pentoxifylline—Palpitations—Ezetimibe—atherosclerosis	0.00188	0.00356	CcSEcCtD
Pentoxifylline—Anaemia—Simvastatin—atherosclerosis	0.00188	0.00355	CcSEcCtD
Pentoxifylline—Erythema—Niacin—atherosclerosis	0.00187	0.00352	CcSEcCtD
Pentoxifylline—Angioedema—Simvastatin—atherosclerosis	0.00186	0.00351	CcSEcCtD
Pentoxifylline—Chest pain—Lovastatin—atherosclerosis	0.00185	0.00349	CcSEcCtD
Pentoxifylline—Myalgia—Lovastatin—atherosclerosis	0.00185	0.00349	CcSEcCtD
Pentoxifylline—Anxiety—Lovastatin—atherosclerosis	0.00184	0.00348	CcSEcCtD
Pentoxifylline—Dyspepsia—Rosuvastatin—atherosclerosis	0.00184	0.00348	CcSEcCtD
Pentoxifylline—Hypertension—Ezetimibe—atherosclerosis	0.00184	0.00347	CcSEcCtD
Pentoxifylline—Flatulence—Niacin—atherosclerosis	0.00184	0.00347	CcSEcCtD
Pentoxifylline—Malaise—Simvastatin—atherosclerosis	0.00183	0.00346	CcSEcCtD
Pentoxifylline—Tension—Niacin—atherosclerosis	0.00183	0.00346	CcSEcCtD
Pentoxifylline—Discomfort—Lovastatin—atherosclerosis	0.00183	0.00345	CcSEcCtD
Pentoxifylline—Leukopenia—Simvastatin—atherosclerosis	0.00182	0.00343	CcSEcCtD
Pentoxifylline—Chest pain—Ezetimibe—atherosclerosis	0.00181	0.00343	CcSEcCtD
Pentoxifylline—Myalgia—Ezetimibe—atherosclerosis	0.00181	0.00343	CcSEcCtD
Pentoxifylline—Nervousness—Niacin—atherosclerosis	0.00181	0.00342	CcSEcCtD
Pentoxifylline—Flatulence—Pravastatin—atherosclerosis	0.00181	0.00342	CcSEcCtD
Pentoxifylline—Dry mouth—Lovastatin—atherosclerosis	0.00181	0.00342	CcSEcCtD
Pentoxifylline—Tension—Pravastatin—atherosclerosis	0.0018	0.0034	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.0018	0.0034	CcSEcCtD
Pentoxifylline—Dysgeusia—Pravastatin—atherosclerosis	0.0018	0.0034	CcSEcCtD
Pentoxifylline—Muscle spasms—Niacin—atherosclerosis	0.00179	0.00339	CcSEcCtD
Pentoxifylline—Discomfort—Ezetimibe—atherosclerosis	0.00179	0.00338	CcSEcCtD
Pentoxifylline—Constipation—Rosuvastatin—atherosclerosis	0.00179	0.00338	CcSEcCtD
Pentoxifylline—Confusional state—Lovastatin—atherosclerosis	0.00179	0.00338	CcSEcCtD
Pentoxifylline—Nervousness—Pravastatin—atherosclerosis	0.00178	0.00337	CcSEcCtD
Pentoxifylline—Dry mouth—Ezetimibe—atherosclerosis	0.00177	0.00335	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Lovastatin—atherosclerosis	0.00177	0.00335	CcSEcCtD
Pentoxifylline—Muscle spasms—Pravastatin—atherosclerosis	0.00177	0.00333	CcSEcCtD
Pentoxifylline—Infection—Lovastatin—atherosclerosis	0.00176	0.00333	CcSEcCtD
Pentoxifylline—Vision blurred—Niacin—atherosclerosis	0.00176	0.00332	CcSEcCtD
Pentoxifylline—Confusional state—Ezetimibe—atherosclerosis	0.00175	0.00331	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00174	0.00328	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Lovastatin—atherosclerosis	0.00174	0.00328	CcSEcCtD
Pentoxifylline—Vision blurred—Pravastatin—atherosclerosis	0.00173	0.00327	CcSEcCtD
Pentoxifylline—Chest pain—Simvastatin—atherosclerosis	0.00173	0.00327	CcSEcCtD
Pentoxifylline—Myalgia—Simvastatin—atherosclerosis	0.00173	0.00327	CcSEcCtD
Pentoxifylline—Infection—Ezetimibe—atherosclerosis	0.00173	0.00326	CcSEcCtD
Pentoxifylline—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00172	0.00326	CcSEcCtD
Pentoxifylline—Anxiety—Simvastatin—atherosclerosis	0.00172	0.00326	CcSEcCtD
Pentoxifylline—Tremor—Pravastatin—atherosclerosis	0.00172	0.00325	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00171	0.00323	CcSEcCtD
Pentoxifylline—Discomfort—Simvastatin—atherosclerosis	0.00171	0.00323	CcSEcCtD
Pentoxifylline—Angioedema—Niacin—atherosclerosis	0.0017	0.00322	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Pravastatin—atherosclerosis	0.0017	0.00322	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Ezetimibe—atherosclerosis	0.0017	0.00321	CcSEcCtD
Pentoxifylline—Anaemia—Pravastatin—atherosclerosis	0.0017	0.00321	CcSEcCtD
Pentoxifylline—Anorexia—Lovastatin—atherosclerosis	0.00169	0.00319	CcSEcCtD
Pentoxifylline—Skin disorder—Ezetimibe—atherosclerosis	0.00169	0.00319	CcSEcCtD
Pentoxifylline—Angioedema—Pravastatin—atherosclerosis	0.00168	0.00317	CcSEcCtD
Pentoxifylline—Confusional state—Simvastatin—atherosclerosis	0.00167	0.00316	CcSEcCtD
Pentoxifylline—Leukopenia—Niacin—atherosclerosis	0.00167	0.00315	CcSEcCtD
Pentoxifylline—Urticaria—Rosuvastatin—atherosclerosis	0.00166	0.00314	CcSEcCtD
Pentoxifylline—Oedema—Simvastatin—atherosclerosis	0.00166	0.00313	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Simvastatin—atherosclerosis	0.00166	0.00313	CcSEcCtD
Pentoxifylline—Malaise—Pravastatin—atherosclerosis	0.00166	0.00313	CcSEcCtD
Pentoxifylline—Abdominal pain—Rosuvastatin—atherosclerosis	0.00165	0.00312	CcSEcCtD
Pentoxifylline—Palpitations—Niacin—atherosclerosis	0.00165	0.00311	CcSEcCtD
Pentoxifylline—Infection—Simvastatin—atherosclerosis	0.00165	0.00311	CcSEcCtD
Pentoxifylline—Leukopenia—Pravastatin—atherosclerosis	0.00164	0.0031	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Simvastatin—atherosclerosis	0.00162	0.00307	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00162	0.00305	CcSEcCtD
Pentoxifylline—Insomnia—Lovastatin—atherosclerosis	0.0016	0.00303	CcSEcCtD
Pentoxifylline—Myalgia—Niacin—atherosclerosis	0.00159	0.003	CcSEcCtD
Pentoxifylline—Hypertension—Pravastatin—atherosclerosis	0.00159	0.00299	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00158	0.00299	CcSEcCtD
Pentoxifylline—Anorexia—Simvastatin—atherosclerosis	0.00158	0.00298	CcSEcCtD
Pentoxifylline—Dyspnoea—Lovastatin—atherosclerosis	0.00158	0.00298	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00158	0.00298	CcSEcCtD
Pentoxifylline—Insomnia—Ezetimibe—atherosclerosis	0.00157	0.00297	CcSEcCtD
Pentoxifylline—Chest pain—Pravastatin—atherosclerosis	0.00156	0.00295	CcSEcCtD
Pentoxifylline—Myalgia—Pravastatin—atherosclerosis	0.00156	0.00295	CcSEcCtD
Pentoxifylline—Dyspepsia—Lovastatin—atherosclerosis	0.00156	0.00295	CcSEcCtD
Pentoxifylline—Anxiety—Pravastatin—atherosclerosis	0.00156	0.00294	CcSEcCtD
Pentoxifylline—Dry mouth—Niacin—atherosclerosis	0.00155	0.00293	CcSEcCtD
Pentoxifylline—Dyspnoea—Ezetimibe—atherosclerosis	0.00155	0.00293	CcSEcCtD
Pentoxifylline—Discomfort—Pravastatin—atherosclerosis	0.00155	0.00292	CcSEcCtD
Pentoxifylline—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00154	0.00291	CcSEcCtD
Pentoxifylline—Decreased appetite—Lovastatin—atherosclerosis	0.00154	0.00291	CcSEcCtD
Pentoxifylline—Dyspepsia—Ezetimibe—atherosclerosis	0.00153	0.00289	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Niacin—atherosclerosis	0.00152	0.00288	CcSEcCtD
Pentoxifylline—Oedema—Niacin—atherosclerosis	0.00152	0.00288	CcSEcCtD
Pentoxifylline—Constipation—Lovastatin—atherosclerosis	0.00152	0.00286	CcSEcCtD
Pentoxifylline—Confusional state—Pravastatin—atherosclerosis	0.00151	0.00285	CcSEcCtD
Pentoxifylline—Decreased appetite—Ezetimibe—atherosclerosis	0.00151	0.00285	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00151	0.00285	CcSEcCtD
Pentoxifylline—Asthenia—Rosuvastatin—atherosclerosis	0.0015	0.00283	CcSEcCtD
Pentoxifylline—Insomnia—Simvastatin—atherosclerosis	0.0015	0.00283	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Pravastatin—atherosclerosis	0.0015	0.00283	CcSEcCtD
Pentoxifylline—Oedema—Pravastatin—atherosclerosis	0.0015	0.00283	CcSEcCtD
Pentoxifylline—Shock—Niacin—atherosclerosis	0.0015	0.00283	CcSEcCtD
Pentoxifylline—Infection—Pravastatin—atherosclerosis	0.00149	0.00281	CcSEcCtD
Pentoxifylline—Constipation—Ezetimibe—atherosclerosis	0.00149	0.00281	CcSEcCtD
Pentoxifylline—Tachycardia—Niacin—atherosclerosis	0.00149	0.00281	CcSEcCtD
Pentoxifylline—Pruritus—Rosuvastatin—atherosclerosis	0.00148	0.00279	CcSEcCtD
Pentoxifylline—Skin disorder—Niacin—atherosclerosis	0.00148	0.00279	CcSEcCtD
Pentoxifylline—Dyspnoea—Simvastatin—atherosclerosis	0.00148	0.00279	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Niacin—atherosclerosis	0.00147	0.00278	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Pravastatin—atherosclerosis	0.00147	0.00277	CcSEcCtD
Pentoxifylline—Feeling abnormal—Lovastatin—atherosclerosis	0.00146	0.00276	CcSEcCtD
Pentoxifylline—Dyspepsia—Simvastatin—atherosclerosis	0.00146	0.00276	CcSEcCtD
Pentoxifylline—Anorexia—Niacin—atherosclerosis	0.00145	0.00274	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00145	0.00274	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Pravastatin—atherosclerosis	0.00145	0.00274	CcSEcCtD
Pentoxifylline—Decreased appetite—Simvastatin—atherosclerosis	0.00144	0.00272	CcSEcCtD
Pentoxifylline—Feeling abnormal—Ezetimibe—atherosclerosis	0.00143	0.00271	CcSEcCtD
Pentoxifylline—Diarrhoea—Rosuvastatin—atherosclerosis	0.00143	0.0027	CcSEcCtD
Pentoxifylline—Anorexia—Pravastatin—atherosclerosis	0.00143	0.0027	CcSEcCtD
Pentoxifylline—Hypotension—Niacin—atherosclerosis	0.00142	0.00269	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00142	0.00268	CcSEcCtD
Pentoxifylline—Constipation—Simvastatin—atherosclerosis	0.00142	0.00268	CcSEcCtD
Pentoxifylline—Urticaria—Lovastatin—atherosclerosis	0.00141	0.00266	CcSEcCtD
Pentoxifylline—Abdominal pain—Lovastatin—atherosclerosis	0.0014	0.00265	CcSEcCtD
Pentoxifylline—Body temperature increased—Lovastatin—atherosclerosis	0.0014	0.00265	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00139	0.00262	CcSEcCtD
Pentoxifylline—Dizziness—Rosuvastatin—atherosclerosis	0.00138	0.00261	CcSEcCtD
Pentoxifylline—Urticaria—Ezetimibe—atherosclerosis	0.00138	0.00261	CcSEcCtD
Pentoxifylline—Insomnia—Niacin—atherosclerosis	0.00138	0.0026	CcSEcCtD
Pentoxifylline—Abdominal pain—Ezetimibe—atherosclerosis	0.00137	0.0026	CcSEcCtD
Pentoxifylline—Body temperature increased—Ezetimibe—atherosclerosis	0.00137	0.0026	CcSEcCtD
Pentoxifylline—Feeling abnormal—Simvastatin—atherosclerosis	0.00137	0.00258	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00137	0.00258	CcSEcCtD
Pentoxifylline—Dyspnoea—Niacin—atherosclerosis	0.00136	0.00256	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00136	0.00256	CcSEcCtD
Pentoxifylline—Insomnia—Pravastatin—atherosclerosis	0.00136	0.00256	CcSEcCtD
Pentoxifylline—Somnolence—Niacin—atherosclerosis	0.00135	0.00256	CcSEcCtD
Pentoxifylline—Dyspepsia—Niacin—atherosclerosis	0.00134	0.00253	CcSEcCtD
Pentoxifylline—CYP1A2—liver—atherosclerosis	0.00134	0.00903	CbGeAlD
Pentoxifylline—Dyspnoea—Pravastatin—atherosclerosis	0.00134	0.00252	CcSEcCtD
Pentoxifylline—Decreased appetite—Niacin—atherosclerosis	0.00132	0.0025	CcSEcCtD
Pentoxifylline—Dyspepsia—Pravastatin—atherosclerosis	0.00132	0.00249	CcSEcCtD
Pentoxifylline—Rash—Rosuvastatin—atherosclerosis	0.00132	0.00249	CcSEcCtD
Pentoxifylline—Dermatitis—Rosuvastatin—atherosclerosis	0.00132	0.00249	CcSEcCtD
Pentoxifylline—Urticaria—Simvastatin—atherosclerosis	0.00132	0.00249	CcSEcCtD
Pentoxifylline—Abdominal pain—Simvastatin—atherosclerosis	0.00131	0.00248	CcSEcCtD
Pentoxifylline—Body temperature increased—Simvastatin—atherosclerosis	0.00131	0.00248	CcSEcCtD
Pentoxifylline—Headache—Rosuvastatin—atherosclerosis	0.00131	0.00247	CcSEcCtD
Pentoxifylline—Hypersensitivity—Lovastatin—atherosclerosis	0.00131	0.00247	CcSEcCtD
Pentoxifylline—Decreased appetite—Pravastatin—atherosclerosis	0.0013	0.00246	CcSEcCtD
Pentoxifylline—Constipation—Pravastatin—atherosclerosis	0.00128	0.00242	CcSEcCtD
Pentoxifylline—Hypersensitivity—Ezetimibe—atherosclerosis	0.00128	0.00242	CcSEcCtD
Pentoxifylline—Asthenia—Lovastatin—atherosclerosis	0.00127	0.0024	CcSEcCtD
Pentoxifylline—Pruritus—Lovastatin—atherosclerosis	0.00125	0.00237	CcSEcCtD
Pentoxifylline—Asthenia—Ezetimibe—atherosclerosis	0.00125	0.00236	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Niacin—atherosclerosis	0.00125	0.00235	CcSEcCtD
Pentoxifylline—Nausea—Rosuvastatin—atherosclerosis	0.00124	0.00235	CcSEcCtD
Pentoxifylline—Feeling abnormal—Pravastatin—atherosclerosis	0.00124	0.00233	CcSEcCtD
Pentoxifylline—Pruritus—Ezetimibe—atherosclerosis	0.00123	0.00232	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00123	0.00231	CcSEcCtD
Pentoxifylline—Hypersensitivity—Simvastatin—atherosclerosis	0.00122	0.00231	CcSEcCtD
Pentoxifylline—Diarrhoea—Lovastatin—atherosclerosis	0.00121	0.00229	CcSEcCtD
Pentoxifylline—Urticaria—Niacin—atherosclerosis	0.00121	0.00228	CcSEcCtD
Pentoxifylline—Abdominal pain—Niacin—atherosclerosis	0.0012	0.00227	CcSEcCtD
Pentoxifylline—Body temperature increased—Niacin—atherosclerosis	0.0012	0.00227	CcSEcCtD
Pentoxifylline—Urticaria—Pravastatin—atherosclerosis	0.00119	0.00225	CcSEcCtD
Pentoxifylline—Asthenia—Simvastatin—atherosclerosis	0.00119	0.00225	CcSEcCtD
Pentoxifylline—Diarrhoea—Ezetimibe—atherosclerosis	0.00119	0.00225	CcSEcCtD
Pentoxifylline—Abdominal pain—Pravastatin—atherosclerosis	0.00119	0.00224	CcSEcCtD
Pentoxifylline—Body temperature increased—Pravastatin—atherosclerosis	0.00119	0.00224	CcSEcCtD
Pentoxifylline—Pruritus—Simvastatin—atherosclerosis	0.00117	0.00222	CcSEcCtD
Pentoxifylline—Dizziness—Lovastatin—atherosclerosis	0.00117	0.00221	CcSEcCtD
Pentoxifylline—Dizziness—Ezetimibe—atherosclerosis	0.00115	0.00217	CcSEcCtD
Pentoxifylline—Diarrhoea—Simvastatin—atherosclerosis	0.00113	0.00214	CcSEcCtD
Pentoxifylline—Vomiting—Lovastatin—atherosclerosis	0.00113	0.00213	CcSEcCtD
Pentoxifylline—Hypersensitivity—Niacin—atherosclerosis	0.00112	0.00212	CcSEcCtD
Pentoxifylline—Rash—Lovastatin—atherosclerosis	0.00112	0.00211	CcSEcCtD
Pentoxifylline—Dermatitis—Lovastatin—atherosclerosis	0.00112	0.00211	CcSEcCtD
Pentoxifylline—Headache—Lovastatin—atherosclerosis	0.00111	0.0021	CcSEcCtD
Pentoxifylline—Vomiting—Ezetimibe—atherosclerosis	0.00111	0.00209	CcSEcCtD
Pentoxifylline—Hypersensitivity—Pravastatin—atherosclerosis	0.0011	0.00209	CcSEcCtD
Pentoxifylline—Dizziness—Simvastatin—atherosclerosis	0.0011	0.00207	CcSEcCtD
Pentoxifylline—Rash—Ezetimibe—atherosclerosis	0.0011	0.00207	CcSEcCtD
Pentoxifylline—Dermatitis—Ezetimibe—atherosclerosis	0.0011	0.00207	CcSEcCtD
Pentoxifylline—Asthenia—Niacin—atherosclerosis	0.00109	0.00206	CcSEcCtD
Pentoxifylline—Headache—Ezetimibe—atherosclerosis	0.00109	0.00206	CcSEcCtD
Pentoxifylline—Pruritus—Niacin—atherosclerosis	0.00108	0.00203	CcSEcCtD
Pentoxifylline—Asthenia—Pravastatin—atherosclerosis	0.00108	0.00203	CcSEcCtD
Pentoxifylline—Pruritus—Pravastatin—atherosclerosis	0.00106	0.002	CcSEcCtD
Pentoxifylline—Vomiting—Simvastatin—atherosclerosis	0.00105	0.00199	CcSEcCtD
Pentoxifylline—Nausea—Lovastatin—atherosclerosis	0.00105	0.00199	CcSEcCtD
Pentoxifylline—Rash—Simvastatin—atherosclerosis	0.00105	0.00197	CcSEcCtD
Pentoxifylline—Dermatitis—Simvastatin—atherosclerosis	0.00104	0.00197	CcSEcCtD
Pentoxifylline—Diarrhoea—Niacin—atherosclerosis	0.00104	0.00197	CcSEcCtD
Pentoxifylline—Headache—Simvastatin—atherosclerosis	0.00104	0.00196	CcSEcCtD
Pentoxifylline—Nausea—Ezetimibe—atherosclerosis	0.00103	0.00195	CcSEcCtD
Pentoxifylline—Diarrhoea—Pravastatin—atherosclerosis	0.00103	0.00194	CcSEcCtD
Pentoxifylline—Dizziness—Niacin—atherosclerosis	0.00101	0.0019	CcSEcCtD
Pentoxifylline—Dizziness—Pravastatin—atherosclerosis	0.000991	0.00187	CcSEcCtD
Pentoxifylline—Nausea—Simvastatin—atherosclerosis	0.000985	0.00186	CcSEcCtD
Pentoxifylline—Vomiting—Niacin—atherosclerosis	0.000968	0.00183	CcSEcCtD
Pentoxifylline—Rash—Niacin—atherosclerosis	0.00096	0.00181	CcSEcCtD
Pentoxifylline—Dermatitis—Niacin—atherosclerosis	0.000959	0.00181	CcSEcCtD
Pentoxifylline—Headache—Niacin—atherosclerosis	0.000954	0.0018	CcSEcCtD
Pentoxifylline—Vomiting—Pravastatin—atherosclerosis	0.000953	0.0018	CcSEcCtD
Pentoxifylline—Rash—Pravastatin—atherosclerosis	0.000945	0.00178	CcSEcCtD
Pentoxifylline—Dermatitis—Pravastatin—atherosclerosis	0.000944	0.00178	CcSEcCtD
Pentoxifylline—Headache—Pravastatin—atherosclerosis	0.000939	0.00177	CcSEcCtD
Pentoxifylline—Nausea—Niacin—atherosclerosis	0.000904	0.00171	CcSEcCtD
Pentoxifylline—Nausea—Pravastatin—atherosclerosis	0.00089	0.00168	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling Pathways—GHRL—atherosclerosis	9.14e-05	0.000284	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PLAT—atherosclerosis	9.14e-05	0.000284	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP3—atherosclerosis	9.1e-05	0.000282	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—LPL—atherosclerosis	9.07e-05	0.000282	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF2—atherosclerosis	9.05e-05	0.000281	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	8.99e-05	0.000279	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOB—atherosclerosis	8.9e-05	0.000276	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—CXCL8—atherosclerosis	8.82e-05	0.000274	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PRKCG—atherosclerosis	8.82e-05	0.000274	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—AKT1—atherosclerosis	8.81e-05	0.000274	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOB—atherosclerosis	8.79e-05	0.000273	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—F2—atherosclerosis	8.78e-05	0.000272	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PDGFB—atherosclerosis	8.75e-05	0.000272	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EDN1—atherosclerosis	8.75e-05	0.000272	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—CXCL8—atherosclerosis	8.72e-05	0.000271	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL5—atherosclerosis	8.69e-05	0.00027	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EDN1—atherosclerosis	8.65e-05	0.000269	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLTP—atherosclerosis	8.64e-05	0.000268	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SPP1—atherosclerosis	8.59e-05	0.000267	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL5—atherosclerosis	8.58e-05	0.000266	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—CXCL8—atherosclerosis	8.55e-05	0.000266	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AGT—atherosclerosis	8.55e-05	0.000265	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—LPL—atherosclerosis	8.49e-05	0.000264	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CG—atherosclerosis	8.4e-05	0.000261	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—LPL—atherosclerosis	8.39e-05	0.000261	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—LEP—atherosclerosis	8.37e-05	0.00026	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—APOE—atherosclerosis	8.37e-05	0.00026	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CAV1—atherosclerosis	8.3e-05	0.000258	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—APOA1—atherosclerosis	8.28e-05	0.000257	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PRKCG—atherosclerosis	8.26e-05	0.000256	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PRKCG—atherosclerosis	8.16e-05	0.000253	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SPP1—atherosclerosis	8.05e-05	0.00025	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KNG1—atherosclerosis	8.02e-05	0.000249	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	8.01e-05	0.000249	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—CXCL8—atherosclerosis	8.01e-05	0.000249	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ESR1—atherosclerosis	7.99e-05	0.000248	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AGTR1—atherosclerosis	7.97e-05	0.000247	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	7.96e-05	0.000247	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PDGFB—atherosclerosis	7.95e-05	0.000247	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SPP1—atherosclerosis	7.95e-05	0.000247	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—CXCL8—atherosclerosis	7.91e-05	0.000246	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	7.91e-05	0.000246	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—F2—atherosclerosis	7.9e-05	0.000245	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CCL2—atherosclerosis	7.82e-05	0.000243	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PLG—atherosclerosis	7.77e-05	0.000241	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AGT—atherosclerosis	7.76e-05	0.000241	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	7.73e-05	0.00024	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—LEP—atherosclerosis	7.6e-05	0.000236	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—APOE—atherosclerosis	7.6e-05	0.000236	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CG—atherosclerosis	7.56e-05	0.000235	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CAV1—atherosclerosis	7.53e-05	0.000234	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—APOA1—atherosclerosis	7.52e-05	0.000233	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCG8—atherosclerosis	7.5e-05	0.000233	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LTA4H—atherosclerosis	7.5e-05	0.000233	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PDGFB—atherosclerosis	7.44e-05	0.000231	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	7.4e-05	0.00023	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SOCS3—atherosclerosis	7.36e-05	0.000228	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PDGFB—atherosclerosis	7.36e-05	0.000228	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AGT—atherosclerosis	7.27e-05	0.000226	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ESR1—atherosclerosis	7.26e-05	0.000225	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—MAPK3—atherosclerosis	7.24e-05	0.000225	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AGT—atherosclerosis	7.18e-05	0.000223	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—F2—atherosclerosis	7.17e-05	0.000223	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—INS—atherosclerosis	7.15e-05	0.000222	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—LEP—atherosclerosis	7.12e-05	0.000221	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOE—atherosclerosis	7.12e-05	0.000221	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP3—atherosclerosis	7.11e-05	0.000221	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF2—atherosclerosis	7.08e-05	0.00022	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CAV1—atherosclerosis	7.05e-05	0.000219	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL2—atherosclerosis	7.04e-05	0.000218	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOA1—atherosclerosis	7.04e-05	0.000218	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—LEP—atherosclerosis	7.04e-05	0.000218	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOE—atherosclerosis	7.04e-05	0.000218	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	6.99e-05	0.000217	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CAV1—atherosclerosis	6.97e-05	0.000216	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOA1—atherosclerosis	6.96e-05	0.000216	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IGF1—atherosclerosis	6.92e-05	0.000215	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOB—atherosclerosis	6.87e-05	0.000213	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CG—atherosclerosis	6.86e-05	0.000213	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—AKT1—atherosclerosis	6.82e-05	0.000212	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—CXCL8—atherosclerosis	6.81e-05	0.000211	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ESR1—atherosclerosis	6.8e-05	0.000211	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EDN1—atherosclerosis	6.76e-05	0.00021	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ESR1—atherosclerosis	6.72e-05	0.000208	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—F2—atherosclerosis	6.71e-05	0.000208	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL5—atherosclerosis	6.71e-05	0.000208	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—F2—atherosclerosis	6.63e-05	0.000206	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—MAPK3—atherosclerosis	6.57e-05	0.000204	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SERPINE1—atherosclerosis	6.57e-05	0.000204	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LPL—atherosclerosis	6.56e-05	0.000204	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—INS—atherosclerosis	6.5e-05	0.000202	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CG—atherosclerosis	6.43e-05	0.000199	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL2—atherosclerosis	6.39e-05	0.000198	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PRKCG—atherosclerosis	6.38e-05	0.000198	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CG—atherosclerosis	6.35e-05	0.000197	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1—atherosclerosis	6.28e-05	0.000195	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NOS3—atherosclerosis	6.27e-05	0.000195	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	6.23e-05	0.000193	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SPP1—atherosclerosis	6.21e-05	0.000193	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCL8—atherosclerosis	6.18e-05	0.000192	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—MAPK3—atherosclerosis	6.15e-05	0.000191	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—INS—atherosclerosis	6.08e-05	0.000189	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—MAPK3—atherosclerosis	6.08e-05	0.000189	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—INS—atherosclerosis	6.01e-05	0.000187	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL2—atherosclerosis	5.98e-05	0.000186	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SERPINE1—atherosclerosis	5.97e-05	0.000185	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCG1—atherosclerosis	5.93e-05	0.000184	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL2—atherosclerosis	5.91e-05	0.000184	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1—atherosclerosis	5.88e-05	0.000183	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1—atherosclerosis	5.81e-05	0.00018	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PDGFB—atherosclerosis	5.75e-05	0.000178	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NOS3—atherosclerosis	5.7e-05	0.000177	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AGT—atherosclerosis	5.61e-05	0.000174	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SERPINE1—atherosclerosis	5.59e-05	0.000173	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FABP4—atherosclerosis	5.57e-05	0.000173	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LCAT—atherosclerosis	5.57e-05	0.000173	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL8—atherosclerosis	5.56e-05	0.000173	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SERPINE1—atherosclerosis	5.52e-05	0.000171	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOE—atherosclerosis	5.5e-05	0.000171	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LEP—atherosclerosis	5.5e-05	0.000171	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA4—atherosclerosis	5.47e-05	0.00017	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CAV1—atherosclerosis	5.45e-05	0.000169	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOA1—atherosclerosis	5.43e-05	0.000169	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—AKT1—atherosclerosis	5.38e-05	0.000167	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP7A1—atherosclerosis	5.37e-05	0.000167	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NOS3—atherosclerosis	5.33e-05	0.000166	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—atherosclerosis	5.29e-05	0.000164	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NOS3—atherosclerosis	5.27e-05	0.000164	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ESR1—atherosclerosis	5.25e-05	0.000163	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—F2—atherosclerosis	5.18e-05	0.000161	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	5.12e-05	0.000159	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—atherosclerosis	5.05e-05	0.000157	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—atherosclerosis	5.03e-05	0.000156	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NFKB1—atherosclerosis	4.98e-05	0.000155	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP27A1—atherosclerosis	4.97e-05	0.000154	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CG—atherosclerosis	4.96e-05	0.000154	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK8—atherosclerosis	4.9e-05	0.000152	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	4.89e-05	0.000152	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—atherosclerosis	4.88e-05	0.000152	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—atherosclerosis	4.88e-05	0.000152	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—atherosclerosis	4.8e-05	0.000149	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	4.77e-05	0.000148	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—MAPK3—atherosclerosis	4.75e-05	0.000147	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—atherosclerosis	4.73e-05	0.000147	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	4.71e-05	0.000146	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA2—atherosclerosis	4.71e-05	0.000146	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	4.71e-05	0.000146	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALOX15—atherosclerosis	4.71e-05	0.000146	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—INS—atherosclerosis	4.7e-05	0.000146	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—atherosclerosis	4.68e-05	0.000145	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCG5—atherosclerosis	4.65e-05	0.000144	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	4.64e-05	0.000144	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL2—atherosclerosis	4.62e-05	0.000143	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—atherosclerosis	4.57e-05	0.000142	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—atherosclerosis	4.57e-05	0.000142	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—atherosclerosis	4.54e-05	0.000141	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NFKB1—atherosclerosis	4.52e-05	0.00014	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—atherosclerosis	4.52e-05	0.00014	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—atherosclerosis	4.52e-05	0.00014	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—atherosclerosis	4.5e-05	0.00014	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPA—atherosclerosis	4.49e-05	0.000139	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—atherosclerosis	4.48e-05	0.000139	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—atherosclerosis	4.45e-05	0.000138	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK8—atherosclerosis	4.44e-05	0.000138	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—atherosclerosis	4.43e-05	0.000138	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—BGN—atherosclerosis	4.35e-05	0.000135	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	4.32e-05	0.000134	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SERPINE1—atherosclerosis	4.31e-05	0.000134	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA5—atherosclerosis	4.31e-05	0.000134	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—atherosclerosis	4.28e-05	0.000133	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK3—atherosclerosis	4.28e-05	0.000133	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NFKB1—atherosclerosis	4.23e-05	0.000131	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—atherosclerosis	4.23e-05	0.000131	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NFKB1—atherosclerosis	4.18e-05	0.00013	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	4.18e-05	0.00013	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK8—atherosclerosis	4.16e-05	0.000129	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—atherosclerosis	4.15e-05	0.000129	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFB1—atherosclerosis	4.15e-05	0.000129	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	4.14e-05	0.000129	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOS3—atherosclerosis	4.12e-05	0.000128	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK8—atherosclerosis	4.11e-05	0.000128	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—atherosclerosis	4.1e-05	0.000127	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—atherosclerosis	4.1e-05	0.000127	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	4.1e-05	0.000127	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—atherosclerosis	4.06e-05	0.000126	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	4.06e-05	0.000126	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	4.05e-05	0.000126	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALOX5—atherosclerosis	4e-05	0.000124	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK3—atherosclerosis	3.88e-05	0.000121	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—atherosclerosis	3.84e-05	0.000119	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—atherosclerosis	3.81e-05	0.000118	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—atherosclerosis	3.8e-05	0.000118	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFB1—atherosclerosis	3.77e-05	0.000117	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—atherosclerosis	3.76e-05	0.000117	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	3.7e-05	0.000115	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—atherosclerosis	3.65e-05	0.000113	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK3—atherosclerosis	3.64e-05	0.000113	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK3—atherosclerosis	3.59e-05	0.000112	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAMPT—atherosclerosis	3.59e-05	0.000111	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	3.57e-05	0.000111	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LIPC—atherosclerosis	3.57e-05	0.000111	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOC3—atherosclerosis	3.55e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—atherosclerosis	3.53e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFB1—atherosclerosis	3.53e-05	0.000109	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LDLR—atherosclerosis	3.52e-05	0.000109	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFB1—atherosclerosis	3.49e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—atherosclerosis	3.47e-05	0.000108	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CETP—atherosclerosis	3.44e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—atherosclerosis	3.3e-05	0.000103	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SCARB1—atherosclerosis	3.3e-05	0.000102	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKB1—atherosclerosis	3.27e-05	0.000101	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK8—atherosclerosis	3.21e-05	9.97e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	3.21e-05	9.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—atherosclerosis	3.2e-05	9.95e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—atherosclerosis	3.13e-05	9.7e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMGCR—atherosclerosis	3.11e-05	9.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—atherosclerosis	2.97e-05	9.21e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—atherosclerosis	2.94e-05	9.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—atherosclerosis	2.88e-05	8.95e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—atherosclerosis	2.84e-05	8.81e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.81e-05	8.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK3—atherosclerosis	2.81e-05	8.71e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCA1—atherosclerosis	2.77e-05	8.61e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFB1—atherosclerosis	2.72e-05	8.45e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—atherosclerosis	2.66e-05	8.25e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—atherosclerosis	2.63e-05	8.15e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—atherosclerosis	2.62e-05	8.13e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—atherosclerosis	2.45e-05	7.61e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—atherosclerosis	2.42e-05	7.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMOX1—atherosclerosis	2.38e-05	7.39e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOB—atherosclerosis	2.28e-05	7.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.22e-05	6.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPL—atherosclerosis	2.18e-05	6.76e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX1—atherosclerosis	2.12e-05	6.59e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CD36—atherosclerosis	2.07e-05	6.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—atherosclerosis	2.05e-05	6.37e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.96e-05	6.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARA—atherosclerosis	1.92e-05	5.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—atherosclerosis	1.89e-05	5.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AGT—atherosclerosis	1.86e-05	5.78e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOE—atherosclerosis	1.82e-05	5.66e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAV1—atherosclerosis	1.81e-05	5.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA1—atherosclerosis	1.8e-05	5.6e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.65e-05	5.11e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—atherosclerosis	1.59e-05	4.93e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—INS—atherosclerosis	1.56e-05	4.84e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—atherosclerosis	1.43e-05	4.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NOS3—atherosclerosis	1.37e-05	4.24e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.25e-05	3.88e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—atherosclerosis	6.28e-06	1.95e-05	CbGpPWpGaD
